1. Scrip
  2. >>Business
  3. >>Earnings

Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger

 
• By Mandy Jackson

Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.

Progress, planning strategy, rise in sales or success in business concept. Future prediction and estimation with high expectations. Development and improvement. Growing graph. Hand stacking tiles. - Image
Allergan's Q3 revenue increased 3.6% to $4.05bn, beating expectations. • Source: Shutterstock

Allergan PLC’s Botox (onabotulinumtoxinA) continued to rise in the face of new competition and Restasis (cyclosporine) held up surprisingly well in third quarter sales reported on 5 November. Also, late-stage research and development programs remained on course ahead of AbbVie Inc.’s pending $63bn acquisition of the company.

There is skepticism that Allergan will add much to AbbVie’s bottom line beyond Botox, but key R&D programs are progressing through late-stage trials with the potential to expand the company’s commercial portfolio in certain therapeutic areas and extend the life of products nearing the loss of patent exclusivity. Allergan’s third quarter total net revenue of $4.05bn was up 3.6% from $3.91bn a year earlier and beat analyst consensus of $3.91bn

More from Earnings

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

More from Business